Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Clinical Trials (London, England)|November 12, 2005
ASTIN: a Bayesian adaptive dose-response trial in acute strokeAndrew P Grieve, Michael KramsJournal of Psychiatric Practice|July 22, 2011
Phase I trials: from traditional to newer approaches part IIMatthew Macaluso, Michael Krams, Sheldon H PreskornJournal of Psychiatric Practice|May 19, 2011
Phase I trials: from traditional to newer approaches. Part IMatthew Macaluso, Michael Krams, Sheldon H PreskornClinical Trials (London, England)|March 27, 2010
Barriers and opportunities for implementation of adaptive designs in pharmaceutical product developmentJudith Quinlan, Brenda Gaydos, Jeff Maca, et al.Journal of Pharmacokinetics and Pharmacodynamics|November 15, 2005
A longitudinal model for non-monotonic clinical assessment scale dataFredrik Jonsson, Scott Marshall, Michael Krams, et al.Journal of Biopharmaceutical Statistics|January 19, 2012
A bayesian dose-finding design adapting to efficacy and tolerability responseS Krishna Padmanabhan, Scott Berry, Vladimir Dragalin, et al.Stroke|June 14, 2003
UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokineticsKennedy R Lees, Hans-Christoph Diener, Kjell Asplund, et al.Clinical Pharmacokinetics|February 21, 2006
Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic proteinScott Marshall, Fiona Macintyre, Ian James, et al.Behavioural Brain Research|June 23, 2005
Assessing combination treatments in acute stroke: preclinical experiencesMei Lu, Michael Krams, Li Zhang, et al.Pharmaceutical Research|August 4, 2005
Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated dispositionE Niclas Jonsson, Fiona Macintyre, Ian James, et al.Pageof 4